440 related articles for article (PubMed ID: 16220860)
21. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of adverse events following immunisation in Australia annual report, 2019.
Dey A; Wang H; Quinn H; Pillsbury A; Glover C; Hickie M; Wood N; Beard F; Macartney K
Commun Dis Intell (2018); 2021 Apr; 45():. PubMed ID: 33934694
[TBL] [Abstract][Full Text] [Related]
23. Surveillance of adverse events following immunisation in Australia annual report, 2020.
Dey A; Wang H; Quinn H; Pillsbury A; Hickie M; Deng L; Wood N; Beard F; Macartney K
Commun Dis Intell (2018); 2022 Jul; 46():. PubMed ID: 35860867
[TBL] [Abstract][Full Text] [Related]
24. Surveillance of adverse events following immunisation in Australia annual report, 2016.
Dey A; Wang H; Quinn H; Cook J; Macartney K
Commun Dis Intell (2018); 2018; 42():. PubMed ID: 30626306
[TBL] [Abstract][Full Text] [Related]
25. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
[TBL] [Abstract][Full Text] [Related]
26. NSW annual report describing adverse events following immunisation, 2010.
Mahajan D; Campbell-Lloyd S; Cook J; Menzies RI
N S W Public Health Bull; 2011 Nov; 22(9-10):196-208. PubMed ID: 22060057
[TBL] [Abstract][Full Text] [Related]
27. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects.
Jain KM; Paul P; LaMontagne DS
Sex Health; 2013 Mar; 10(1):57-63. PubMed ID: 23237538
[TBL] [Abstract][Full Text] [Related]
28. Active surveillance study of adverse events following immunisation of children in the Czech Republic.
Danova J; Kocourkova A; Celko AM
BMC Public Health; 2017 Feb; 17(1):167. PubMed ID: 28166783
[TBL] [Abstract][Full Text] [Related]
29. Surveillance of adverse events following immunisation in Australia, 2012.
Mahajan D; Dey A; Cook J; Harvey B; Menzies RI; Macartney KM
Commun Dis Intell Q Rep; 2014 Sep; 38(3):E232-46. PubMed ID: 25391415
[TBL] [Abstract][Full Text] [Related]
30. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018.
Clothier HJ; Lawrie J; Lewis G; Russell M; Crawford NW; Buttery JP
Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32536336
[TBL] [Abstract][Full Text] [Related]
31. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system.
Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J
Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
[TBL] [Abstract][Full Text] [Related]
33. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
[TBL] [Abstract][Full Text] [Related]
34. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria.
Clothier HJ; Crawford NW; Kempe A; Buttery JP
Commun Dis Intell Q Rep; 2011 Dec; 35(4):294-8. PubMed ID: 22624490
[TBL] [Abstract][Full Text] [Related]
35. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.
Šubelj M; Učakar V; Kraigher A; Klavs I
Euro Surveill; 2016; 21(14):. PubMed ID: 27103551
[TBL] [Abstract][Full Text] [Related]
36. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
37. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
[TBL] [Abstract][Full Text] [Related]
38. Surveillance of adverse events following immunisation in Australia, 2015.
Dey A; Wang H; Quinn H; Cook J; Macartney K
Commun Dis Intell Q Rep; 2017 Sep; 41(3):E264-E278. PubMed ID: 29720075
[TBL] [Abstract][Full Text] [Related]
39. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
[TBL] [Abstract][Full Text] [Related]
40. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
